[HTML][HTML] Chemotherapeutic drug delivery by tumoral extracellular matrix targeting

R Raavé, TH van Kuppevelt, WF Daamen - Journal of Controlled Release, 2018 - Elsevier
Systemic chemotherapy is a primary strategy in the treatment of cancer, but comes with a
number of limitations such as toxicity and unfavorable biodistribution. To overcome these …

Proteoglycans—biomarkers and targets in cancer therapy

D Nikitovic, A Berdiaki, I Spyridaki… - Frontiers in …, 2018 - frontiersin.org
Proteoglycans (PGs), important constituents of the extracellular matrix, have been
associated with cancer pathogenesis. Their unique structure consisting of a protein core and …

Biodegradable polymers: an update on drug delivery in bone and cartilage diseases

AC Lima, H Ferreira, RL Reis… - Expert Opinion on Drug …, 2019 - Taylor & Francis
Introduction: The unique structure of bone and cartilage makes the systemic delivery of free
drugs to those connective tissues very challenging. Consequently, effective and targeted …

Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma

D Ghedira, A Voissière, C Peyrode, J Kraiem… - European Journal of …, 2018 - Elsevier
Due to an abundant chondrogenic, poorly vascularized and particularly hypoxic extracellular
matrix, chondrosarcoma, a malignant cartilaginous tumour, is chemo-and radio-resistant …

Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy

Y Gerard, A Voissiere, C Peyrode, MJ Galmier… - Bioorganic …, 2020 - Elsevier
The tumor microenvironment in chondrosarcoma (CHS), a chemo-and radio-resistant cancer
provides unique hallmarks for develo** a chondrosarcoma targeted drug‐delivery system …

[HTML][HTML] Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept

A Voissiere, V Weber, Y Gerard, F Rédini, F Raes… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Due to its abundant chondrogenic matrix and hypoxic tissue, chondrosarcoma is chemo-and
radio-resistant. Our group has developed a proteoglycan targeting strategy by using a …

Assessment of 99mTc-NTP 15-5 uptake on cartilage, a new proteoglycan tracer: Study protocol for a phase I trial (CARSPECT)

E Thivat, M Chanchou, S Mathieu, S Levesque… - Frontiers in …, 2022 - frontiersin.org
Background 99mTc-NTP 15-5 is a SPECT radiotracer targeting proteoglycans (PG),
components of the cartilaginous extracellular matrix. Imaging of PGs would be useful for the …

Synthèse de prodrogues bispécifiques activables en milieu hypoxique: application au traitement du chondrosarcome et nouvelles perspectives dans le cadre du …

Y Gerard - 2018 - theses.hal.science
Le chondrosarcome (CHS), cancer du cartilage est une tumeur chimio-et radiorésistance
dont le seul traitement efficace reste la chirurgie. Une prodrogue vectorisée et activable en …

Design, Synthesis and in Vitro Evaluation of Diclofenac and Naproxen Prodrugs as Targeted Anti-Inflammatory Agents for Osteoarthritis

I Voitovich, N Ty, M Couderc, C Peyrode… - Caroline and WEBER … - papers.ssrn.com
Design, synthesis and in vitro evaluation of diclofenac and naproxen prodrugs as targeted
anti-inflammatory agents for osteoarth Page 1 Design, synthesis and in vitro evaluation of …

Assessment of mTc-NTP-uptake on cartilage, a new proteoglycan tracer: Study protocol for a phase I trial (CARSPECT)

C Shen, S Annunziata, E Thivat - Nuclear medicine in …, 2023 - books.google.com
Background: m Tc-NTP-is a SPECT radiotracer targeting proteoglycans (PG), components of
the cartilaginous extracellular matrix. Imaging of PGs would be useful for the early detection …